Skip to content
Companies

Shuttle Pharmaceuticals

Radiation-sensitizing drug for glioblastoma

Raised to date

$10M

of $10M offered across 1 Form D filing

Investors
47
Last filed
May 15, 2026

About

Shuttle Pharmaceuticals is a clinical-stage pharmaceutical company in Gaithersburg, Maryland, founded in 2012 by faculty of the Georgetown University Medical Center and listed on Nasdaq as SHPH. It develops radiation sensitizers and related diagnostics intended to improve outcomes for cancer patients treated with radiation therapy. Its lead candidate, Ropidoxuridine (IPdR), received an FDA 'safe to proceed' letter in January 2024 and is enrolling patients in a Phase 2 trial in newly diagnosed IDH-wildtype, MGMT-unmethylated glioblastoma at sites including Georgetown, UNC, UVA and Miami Cancer Institute. The company also markets Molecule.ai, an AI-driven software platform for molecular discovery and early-stage drug development.

Rather than attacking tumors directly, its lead compound is designed to make cancer cells more sensitive to radiation therapy that patients already receive, and it holds FDA Orphan Drug Designation in glioblastoma.

Funding

  • EquityFiled May 15, 2026Form D
    $10M/ $10M

Product

Ropidoxuridine (IPdR)

Oncology drug candidate

An orally administered radiation-sensitizing drug candidate given alongside radiotherapy, currently in a Phase 2 clinical trial in newly diagnosed IDH-wildtype glioblastoma with an unmethylated MGMT promoter.

  • Oral radiation sensitizer used in combination with radiotherapy
  • FDA 'safe to proceed' letter received January 2024 for the Phase 2 study
  • FDA Orphan Drug Designation for glioblastoma

Built for

Radiation oncologists and cancer centers treating patients with glioblastoma and other radiation-treated solid tumors, plus drug-discovery researchers for the Molecule.ai platform

People on file